-
TD Biologics announces the latest advances in the clinical trial of CFI-402411, a first-of-its-kind HPK1 inhibitor, at the 2022 STIC Annual Meeting
Time of Update: 2023-01-06
1/2study: Hematopoietic Progenitor Kinase-1(HPK1)InhibitorCFI-402411as a Single Agent and in Combination with Pembrolizumab for the Treatment of Subjects with Advanced Solid MalignanciesAbout CFI-402411 CFI-402411 is a highly potent HPK1inhibitor that has been shown to have immunoactivating effects including mitigating inhibitory effects on T cell receptors (TCRs), disrupting abnormal expression of cytokines, and altering the tumor immunosuppressive environment through effector cells (i.
-
Brazil recently approved the registration of 46 plant protection products, including a variety of new pest control biological products
Time of Update: 2023-01-05
Chinese The latest of all products registered includes a low-toxicity product containing a new active ingredient, the Humus bacterium granulovirus (PhopGV, genus Bisporus, Baculoviridae), for the control of tomato moths, which is an excellent choice for controlling this pest.
-
Teripulimab submits UK marketing application Junshi Biologics enters Europe and takes the next city
Time of Update: 2023-01-05
Dr. Patricia Keegan, Chief Medical Officer of Junshi Biologics, said, "This month, we submitted our marketing applications for teripulimab to two major European regulatory agencies, which reflects the company's strong determination and efficient execution to promote innovative drugs for the benefit of patients around the world.
-
TD Biologics announces the latest clinical trial progress of the CFI-402257 and CFI-400945 programs at the 2022 San Antonio Breast Cancer Conference
Time of Update: 2023-01-05
" " Information on the four abstracts: SUMMARY: Recent advances in the Phase 1 clinical trial of CFI-402257 (oral TTK inhibitor) in patients with advanced solid tumors in the HER2-negative breast cancer expansion cohort Poster ID: P6-10-13 Session: Therapeutics: Therapeutic Strategies - New Targets and Targeted Drugs Date: Friday, December 9, 2022 Time: 7:00 a.
-
Junshi Biologics announced that it has submitted a marketing authorization application
Time of Update: 2023-01-05
Dr. Patricia Keegan, Chief Medical Officer of Junshi Biologics, said, "This month, we submitted our marketing applications for teripulimab to two major European regulatory agencies, which reflects the company's strong determination and efficient execution to promote innovative drugs for the benefit of patients around the world.
-
WuXi Biologics successfully held the "Continuous Innovation - Empowering R&D" Summit Forum
Time of Update: 2023-01-05
As one of the important sub-forums of the shared and open section of the "Zhangjiang Life Science International Innovation Summit", this forum attracted more than 100 professionals to share and discuss cutting-edge technologies and insights in the field of biomedicine from different perspectives, and jointly explore how to use appropriate business models to solve R&D challenges and accelerate drug innovation.
-
break through, the country of biological medicine is approaching step by step?
Time of Update: 2023-01-05
On November 16, the results of the proposed selection of drugs in Hebei Province, which lasted for half a month, were officially announced, with a total of 51 varieties (98 drugs) to be selected, involving 74 manufacturers, including the exclusive anticancer drug elemi injection of CSPC Pharmaceutical Group, rabeprazole sodium for injection for non-medical gastric ulcer treatment drug of Shandong Luoxin Pharmaceutical, and oxacillin sodium for injection of star antibacterial drug of Beite Pharmaceutical.
-
TD Biologics announces the latest advances in the clinical trial of the first-of-its-kind HPK1 inhibitor, CFI-402411, at the 2022 STIC Annual Meeting
Time of Update: 2023-01-05
TD Biologics, a clinical-stage biotechnology company developing new cancer drugs, announced on November 11 that CFI-402411, the world's first oral inhibitor of hematopoietic progenitor cell kinase 1
-
Teripulimab submits UK marketing application Junshi Biologics enters Europe and takes the next city
Time of Update: 2023-01-04
js?cdnversion='+~(-new Date()/36e5)]; This is the second marketing application for teripulimab in Europe, and its global commercialization is progressing steadily On November 24, 2022, Beijing time, Junshi Biologics (1877.
-
The national standard "GB 41918-2022 Biological Safety Cabinet" was released
Time of Update: 2023-01-04
【Chemical machinery and equipment network industry news】Biological safety cabin. BSC) is a box-type air purification negative pressure safety device that can prevent aerosol dissipation of certain da
-
Longjing Water's high-efficiency biological denitrification technology has been successfully put
Time of Update: 2023-01-04
Original: Longjing Water's high-efficiency biological nitrogen removal technology was successfully put into operation in the field of coal chemical gasification wastewater 【Chemical Machinery and Equipment Network Star Enterprise】Recently, the heart-to-heart sewage terminal energy efficiency improvement project undertaken by Longjing Environmental Protection successfully completed the 168 performance assessment.
-
Reed Biologics announces a Phase II clinical collaboration with Bristol-Myers Squibb to evaluate
Time of Update: 2023-01-01
Lijin Biologics, an innovative biotechnology company focused on the development and commercialization of first-in-class and best-in-class oncology biologics, today announced the opening of an open-label, multicenter, randomized Phase II clinical trial to evaluate the efficacy and safety of LVGN7409 in combination with docetaxel or nivolumab in combination with Bristol-Myers Squibb in advanced/metastatic non-small cell lung cancer (NSCLC).
-
Characterization of the gut flora of representative mouse strains of AMEM: implications for biological studies
Time of Update: 2023-01-01
Laboratory animals are used to study physiological phenomena, pathological mechanisms and disease prevention. The gut microbiota is considered a potential confounding factor for inconsistent data from
-
Innovent Biologics presented Phase I clinical data for the monotherapy of solid tumors with IBI351
Time of Update: 2023-01-01
Innovent Biopharmaceutical Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sales of innovative drugs in the field of major diseases such as on
-
The study found "there may be a biological and genetic overlap" between carpal tunnel syndrome and migraine
Time of Update: 2023-01-01
" A study in the December issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgery (ASPS), reported that patients who underwent surgery for carpal tunnel syndrome and other upper extremity nerve compression syndromes were more likely to be diagnosed with migraine.